Protein disulphide isomerase-mediated LA419– NO release provides additional antithrombotic effects to the blockade of the ADP receptor

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2007: 97/4 (Apr) pp. 501-684
Pages: 650-657

Protein disulphide isomerase-mediated LA419– NO release provides additional antithrombotic effects to the blockade of the ADP receptor

Gemma Vilahur, Esther Pena, Teresa Padró, Lina Badimon
Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau, UAB, Barcelona, Spain


thrombosis, Platelets, nitric oxide


Despite the proven efficacy of current antithrombotic therapy in preventing ischemic heart disease (IHD), vascular events still occur. Our aims were i) to evaluate if combined oral treatment of clopidogrel and LA419, a novel nitric oxide donor with antiischemic and antiplatelet properties, provides additional antiplatelet effects to those of the blockade of P2Y12 receptor; and ii) to gain insight into the mechanism behind LA419 antiplatelet effects. Pigs (n=16) were randomized into four groups: 1) placebocontrol; 2) LA419; 3) clopidogrel; and 4) LA419+clopidogrel. Both compounds were administered orally: LA419 0.9 mg kg-1 twice daily for 10 days; clopidogrel 10 mg kg-1 day the three last days. Antithrombotic effects were assessed by measuring platelet deposition (PD) triggered by denuded and disrupted vessel wall placed on the Badimon chamber. LA419 effects on platelet aggregation, hemodynamic parameters, and platelet protein expression upon in vitro thrombin stimulation were also evaluated. Total PD on denuded vessels was similarly reduced by all treatments with respect to placebo (p<0.05). However, combination of LA419+clopidogrel largely reduced PD triggered by disrupted vessel wall by 80% versus placebo (p<0.005), 15% versus clopidogrel alone (p<0.01), and 30% versus LA419 alone (p<0.005). All treatments inhibited collagen- and ADP-induced platelet aggregation, and no variations were detected in hemodynamic parameters.Proteomic analysis revealed that LA419 was associated with an increase in membrane protein disulphide isomerase (protein implicated in nitric oxide release).Treatment with LA419 may result in additional antiplatelet effect to that of clopidogrel in addition to restoring impaired endothelial dependent vasodilation without hemodynamic side effects. Further studies in IHD patients seem warranted.

You may also be interested in...

Ok-Nam Bae* 1, Young-Dae Kim* 1, Kyung-Min Lim 1,2, Ji-Yoon Noh 1, Seung-Min Chung 1, Keunyoung Kim 1, Suyoung Hong 1, Sue Shin 3, Jong-Hyun Yoon 3, Jin-Ho Chung1

Thromb Haemost 2008 100 1: 52-59


Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis

Krzysztof Karnicki 2, Robert J. Leadley Jr. 3, Sangita Baxi 3, Thomas Peterson3,Waldemar Wysokinski 1,2, Robert D. McBane, II1,2

Thromb Haemost 2008 99 4: 759-766

A. J. Reininger

Hämostaseologie 2007 27 4: 247-250